Medicis & ReVance Therapeutics announce agreement to develop next-gen Neurotoxin

July 29, 2009

By Flinn Foundation

[Source: GLOBE NEWSWIRE] – Medicis Pharmaceutical Corporation and Revance Therapeutics, Inc. (Revance) today announced that the companies have entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to Revance’s novel, investigational, injectable botulinum toxin type A product (RT002) currently in pre-clinical studies. The objective of the RT002 program is the development of a next-generation neurotoxin with favorable duration of effect and safety profiles.

For more information: Medicis (MRX) and ReVance Therapeutics, Inc. Announce Agreement for Development of Next-Gen Neurotoxin; Revance to Receive $10M